Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of pterostilbene in preparing medicine for preventing and treating high uric acid nephropathy

A high uric acid nephropathy, pterostilbene technology, applied in the field of medicine, can solve the problems of patients' intolerance and limit the clinical application of allopurinol

Inactive Publication Date: 2018-11-09
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, allopurinol is the first-line drug used clinically to lower uric acid, but it can cause adverse reactions such as skin allergies and bone marrow suppression, especially Stevens-Johnson syndrome and toxic epidermal necrolysis, with a mortality rate of 10%. ~40%, these adverse reactions limit the clinical application of allopurinol to some extent
Moreover, allopurinol is metabolized by the kidneys. For patients with renal insufficiency, it is often necessary to adjust the dose according to the glomerular filtration rate, otherwise the patient is not easy to tolerate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of pterostilbene in preparing medicine for preventing and treating high uric acid nephropathy
  • Use of pterostilbene in preparing medicine for preventing and treating high uric acid nephropathy
  • Use of pterostilbene in preparing medicine for preventing and treating high uric acid nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Pterostilbene inhibits the effect of renal interstitial fibrosis

[0040] Experimental animals: wild C57BL / 6J mice. At least 1 week before the experiment, the rats were fed with a standardized experimental diet in a constant temperature environment, with unlimited drinking water.

[0041]Animal grouping: 24 mice were divided into 4 groups: ① sham operation group, 12; ② unilateral ureteral ligation renal interstitial fibrosis (UUO) model group, 12; ③ pterostilbene treatment group with different concentrations (25mg / kg / d, 50mg / kg / d) 6 rats in each group.

[0042] Modeling method: the mice were anesthetized. After anesthesia to judge the approximate projection position of the kidney on the body surface, cut the skin on the left abdomen of the mouse, bluntly separate the subcutaneous tissue and muscle layer, expose the left kidney, look for the ureter along the renal pedicle to the lower pole of the kidney, and make a double line on the upper part of the ureter...

Embodiment 2

[0052] The effect of embodiment 2 pterostilbene treating hyperuricemia nephropathy

[0053] Experimental animals: SPF grade male C57BL / 6J mice. At least 1 week before the experiment, the rats were fed with a standardized experimental diet in a constant temperature environment, with unlimited drinking water.

[0054] Animal grouping: 40 mice were divided into 4 groups: ① normal control group, 10; ② hyperuric acid nephropathy model group, 10; ③ pterostilbene treatment group (50 mg / kg / d) 10; ④ positive control, allopurinol Treatment group (5mg / kg / d) 10.

[0055] Modeling method: According to the weight of the mouse, the ratio of adenine 100mg / kg and oxonate potassium 1500mg / kg was mixed with distilled water to make a suspension with a final concentration of 80g / L, which was administered orally every morning and evening , for 21 consecutive days to establish an animal model of hyperuricemia renal damage. After 21 days, the mice were sacrificed, blood was collected from the abdo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to use of pterostilbene in preparing a medicine for preventing and treating high uric acid nephropathy, and belongs to the field of medicine, and provides use of the pterostilbene or a pharmaceutically acceptable salt thereof in preparing the medicine for treating and / or preventing the high uric acid nephropathy. Experimental results show that the pterostilbene can significantly reduce the level of serum uric acid, inhibits renal interstitial fibrosis, can significantly reduce the expression of fibrosis-related proteins such as alpha-SMA, collagenI, collagenIV and fibronectin, has a definite therapeutic effect on the high uric acid nephropathy, and provides a new option for clinical medication.

Description

technical field [0001] The invention relates to the use of pterostilbene in the preparation of medicines for preventing and treating hyperuricemia nephropathy, which belongs to the field of medicine. Background technique [0002] Hyperuricemia nephropathy is abnormal purine metabolism, kidney damage caused by elevated blood uric acid, early manifested as decreased urine concentration function, and then gradually decreased glomerular filtration rate, increased serum creatinine, leading to chronic renal insufficiency. In recent years, with the increasing incidence of hyperuricemia, the incidence of hyperuricemia nephropathy has increased significantly year by year. Therefore, it is of great significance to seek effective drugs for the treatment of hyperuricemia nephropathy. [0003] Previous studies have confirmed that reducing blood uric acid levels can delay the progression of kidney disease. Therefore, the treatment of hyperuricemia nephropathy focuses on reducing blood ur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/09A61P19/06A61P13/12
CPCA61K31/09A61P13/12A61P19/06
Inventor 马良冯延欢潘静郭帆付平
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com